search
Back to results

Multi-Center Pilot Study of Cutera truSculpt Device

Primary Purpose

Treatment for Cellulite on the Stomach and Flanks

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Cutera truSculpt Device
Sponsored by
Cutera Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Treatment for Cellulite on the Stomach and Flanks

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • 1. Subject must be able to read, understand and sign the Informed Consent Form.

    2. Female or Male, 18 to 65 years of age (inclusive). 3. Subject has visible fat bulges in the area to be treated. 4. Non-smoking for at least 6 months and willing to refrain from smoking for the duration of the study.

    5. Subject must agree to not undergo any other procedure(s) in the treatment region during the study period.

    6. Subject must adhere to the follow-up schedule and study instructions. 7. Subject must adhere to the same diet and/or exercise routine throughout the study, and agree to maintain the same weight throughout the study.

    8. Willing to have photographs taken of the treatment area and agree to use of photographs for presentation, (educational and/or marketing), publications, and any additional marketing purposes.

    9. For female subjects: not pregnant or lactating and is either post-menopausal, surgically sterilized, or using a medically acceptable form of birth control prior to enrollment and during the entire course of the study.

Exclusion Criteria:

  1. Participation in a clinical trial of another device or drug within 1 month of study participation, or during the study period.
  2. Any type of prior cosmetic treatment to the target area within 6 months of study participation.
  3. Any prior invasive cosmetic surgery to the target area, such as liposuction.
  4. Has a pacemaker, internal defibrillator, implantable cardioverter-defibrillator, nerve stimulator implant, cochlear implant or any other electronically, magnetically or mechanically activated implant.
  5. Has metal implant(s) within the body, such as artificial heart valves.
  6. Significant uncontrolled concurrent illness that in the opinion of the Investigator would make the subject unsuitable for inclusion.
  7. History of any disease or condition that could impair wound healing.
  8. History of keloid formation, hypertrophic scarring or abnormal/delayed wound healing.
  9. Skin abnormality in the treatment area that in the opinion of the Investigator would make the subject unsuitable for inclusion.
  10. Currently undergoing systemic chemotherapy or radiation treatment for cancer, or history of treatment in the target area within 3 months of study participation.
  11. Allergy or sensitivity to Tegaderm.
  12. As per the Investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study or a condition that would compromise the subject's ability to comply with the study requirements.

Sites / Locations

  • Laser and Skin Surgery Center of Northern California
  • Advanced Dermatology
  • Union Square Dermatology

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Treatment with the truSculpt RF device

Arm Description

Subjects will be treated with the truSculpt RF device

Outcomes

Primary Outcome Measures

GAIS at 12 Weeks Post Final Treatment
Global Aesthetic Improvement Scale will be assessed at 12 weeks post final treatment by the investigator by comparing against Baseline photos Higher scores indicate better outcomes 0= No change Mild Improvement Moderate improvement Significant Improvement

Secondary Outcome Measures

Full Information

First Posted
December 17, 2018
Last Updated
August 21, 2023
Sponsor
Cutera Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT03782545
Brief Title
Multi-Center Pilot Study of Cutera truSculpt Device
Official Title
Multi-Center Pilot Study of Cutera truSculpt Device
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Completed
Study Start Date
May 11, 2018 (Actual)
Primary Completion Date
December 19, 2018 (Actual)
Study Completion Date
December 19, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Cutera Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Exploratory study to evaluate the safety, efficacy and ergonomics of Cutera truSculpt device.
Detailed Description
This study will evaluate the safety, efficacy and ergonomics of Cutera truSculpt device.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Treatment for Cellulite on the Stomach and Flanks

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
A type of intervention model describing a clinical trial in which all participants receive the same intervention/treatment.
Masking
None (Open Label)
Masking Description
This is an open label study.
Allocation
N/A
Enrollment
34 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Treatment with the truSculpt RF device
Arm Type
Experimental
Arm Description
Subjects will be treated with the truSculpt RF device
Intervention Type
Device
Intervention Name(s)
Cutera truSculpt Device
Intervention Description
The Cutera truSculpt Device uses radio frequency (RF) energy to provide topical heating for the purpose of elevating tissue temperature for the treatment of selected medical conditions, such as temporary reduction in the appearance of cellulite.
Primary Outcome Measure Information:
Title
GAIS at 12 Weeks Post Final Treatment
Description
Global Aesthetic Improvement Scale will be assessed at 12 weeks post final treatment by the investigator by comparing against Baseline photos Higher scores indicate better outcomes 0= No change Mild Improvement Moderate improvement Significant Improvement
Time Frame
12 weeks post final treatment

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: 1. Subject must be able to read, understand and sign the Informed Consent Form. 2. Female or Male, 18 to 65 years of age (inclusive). 3. Subject has visible fat bulges in the area to be treated. 4. Non-smoking for at least 6 months and willing to refrain from smoking for the duration of the study. 5. Subject must agree to not undergo any other procedure(s) in the treatment region during the study period. 6. Subject must adhere to the follow-up schedule and study instructions. 7. Subject must adhere to the same diet and/or exercise routine throughout the study, and agree to maintain the same weight throughout the study. 8. Willing to have photographs taken of the treatment area and agree to use of photographs for presentation, (educational and/or marketing), publications, and any additional marketing purposes. 9. For female subjects: not pregnant or lactating and is either post-menopausal, surgically sterilized, or using a medically acceptable form of birth control prior to enrollment and during the entire course of the study. Exclusion Criteria: Participation in a clinical trial of another device or drug within 1 month of study participation, or during the study period. Any type of prior cosmetic treatment to the target area within 6 months of study participation. Any prior invasive cosmetic surgery to the target area, such as liposuction. Has a pacemaker, internal defibrillator, implantable cardioverter-defibrillator, nerve stimulator implant, cochlear implant or any other electronically, magnetically or mechanically activated implant. Has metal implant(s) within the body, such as artificial heart valves. Significant uncontrolled concurrent illness that in the opinion of the Investigator would make the subject unsuitable for inclusion. History of any disease or condition that could impair wound healing. History of keloid formation, hypertrophic scarring or abnormal/delayed wound healing. Skin abnormality in the treatment area that in the opinion of the Investigator would make the subject unsuitable for inclusion. Currently undergoing systemic chemotherapy or radiation treatment for cancer, or history of treatment in the target area within 3 months of study participation. Allergy or sensitivity to Tegaderm. As per the Investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study or a condition that would compromise the subject's ability to comply with the study requirements.
Facility Information:
Facility Name
Laser and Skin Surgery Center of Northern California
City
Sacramento
State/Province
California
ZIP/Postal Code
95816
Country
United States
Facility Name
Advanced Dermatology
City
Glencoe
State/Province
Illinois
ZIP/Postal Code
60022
Country
United States
Facility Name
Union Square Dermatology
City
New York
State/Province
New York
ZIP/Postal Code
10003
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Researchers involved in the study will have access to the final study data.

Learn more about this trial

Multi-Center Pilot Study of Cutera truSculpt Device

We'll reach out to this number within 24 hrs